A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 \[PD-1\] inhibitor).
Epistemonikos ID: 7c5fe7821b485d267911a354e7cc17ce9908b91f
First added on: May 13, 2024